요약
Fifty 1 Labs (USOTC:FITY) has outlined plans to develop a U. S.
본문
Fifty 1 Labs Outlines Planned U.S. Telehealth Peptide Services Platform
Fiona Craig
USOTC:FITY Latest News August 07 2026 11:00AM
© rawpixel
Fifty 1 Labs (USOTC:FITY) has outlined plans to develop a U.S.-focused telehealth peptide services platform designed to complement its peptide science and commercialization strategy, although the initiative remains subject to regulatory, operational and financing milestones before launch.
Key Investor Takeaways
- Fifty 1 Labs (USOTC:FITY) unveiled its planned telehealth peptide platform as part of its broader commercialization strategy.
- The proposed model would include digital patient intake, clinician evaluations, prescription routing and ongoing patient support through subscription-based services.
- Management expects the platform could generate recurring revenue through memberships, consultations, care management and related healthcare services.
- The telehealth initiative remains in the planning stage and is contingent on regulatory review, technology development, clinician contracting and financing.
- The company stated it does not intend to promote peptides for unapproved uses and plans to structure the platform to comply with healthcare regulations.
Why FITY Stock Is in Focus
Fifty 1 Labs provided investors with an overview of its planned U.S. telehealth services platform, which is intended to operate separately from its investigational clinical development programmes.
Under the proposed model, patients would complete a digital intake process before receiving evaluations from appropriately licensed healthcare professionals through virtual or in-person consultations. Where a clinician determines that peptide therapy is medically appropriate and legally available, prescriptions could be transmitted to qualified compounding pharmacies for dispensing.
The company said it expects the platform to generate revenue through monthly memberships, virtual consultation fees, care-management services, laboratory and monitoring coordination, patient support programmes and certain pharmacy-related service arrangements where legally permitted.
Why This Matters for Investors
The announcement signals that Fifty 1 Labs is seeking to diversify beyond research and development by establishing a patient-facing healthcare services business with the potential for recurring revenue.
However, the platform remains a forward-looking initiative rather than an operational business. Its launch depends on multiple milestones, including regulatory review, state-by-state legal analysis, clinician recruitment, pharmacy integration, technology development, insurance arrangements and financing.
For investors, execution will likely be more important than the platform’s proposed design. While subscription-based healthcare services could broaden the company’s commercial opportunities, the timing and financial impact remain uncertain until the required approvals and infrastructure are in place.
What to Watch Next
Investors should monitor updates on regulatory progress, clinician and pharmacy partnerships, financing, technology development and any announced launch timeline. Additional details on commercial rollout, patient adoption and revenue expectations will likely be key indicators of whether the telehealth strategy advances from planning into execution.
Join the discussion: Connect with other investors on your favorite stocks or explore the top-talked-about stocks on our Breakout Boards.
This article was written by the editorial team at InvestorsHub/ADVFN and is provided for informational purposes only. In some cases, editorial staff may use artificial intelligence–based tools to assist in the research, drafting, or editing of content, under human review and oversight. This article does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. The views expressed are based on publicly available information believed to be reliable at the time of publication, but accuracy or completeness is not guaranteed. Readers should conduct their own independent research and consult a qualified financial professional before making any investment decisions.
Fifty 1 Labs Outlines Planned U.S. Telehealth Peptide Services Platform
Fifty 1 Labs (USOTC:FITY) has outlined plans to develop a U.S.-focused...
Login/Register Top Stories More News
SocGen Raises S&P 500 Target to 8,000 as Earnings Momentum Spreads
Could Copper’s Tariff-Driven Rally Be Running Out of Steam?
UK Stocks Could Prove More Resilient Than U.S. Equities if AI Boom Unravels
Weak July Jobs Report Eases Rate Fears as S&P 500 Sets a Record
Wendy’s Tops Second-Quarter Expectations but Cuts Dividend and Suspends 2026 Guidance
U.S. Stocks Poised for Higher Open as Weak Jobs Report Boosts Rate Cut Hopes: Dow Jones, S&P, Nasdaq, Wall Street Futures
More NewsFITY Discussion
View Posts
Crazyjb
23 hours ago
Back up we go!!!
👍️0
Kjv
24 hours ago
$FITY is expanding its vision! Fifty 1 Labs outlines plans for a U.S. telehealth peptide platform. Big things ahead! 🇺🇸 #Telehealth #Peptides #Biotechnology #Biotechhttps://t.co/LeeDKt5KPh pic.twitter.com/CXPXZNfq1q— Fifty 1 Labs $FITY (@Fifty1Labs) August 7, 2026
👍️0
Kjv
24 hours ago
Sorry
👍️0
2times2
24 hours ago
exactly
👍️0
Kjv
24 hours ago
Maybe we were talking about 2s then and not 3s
👍️0
2times2
24 hours ago
5/20 and 6/8 I bought 7m at 0003!!!!! Sold between 0006 and 0009...gave me 6M freebies now :)
👍️0
ace65
24 hours ago
Well took a ton of buys but .0006s up...nice 10 milly bid showed up.
👍️0
AverageJoe
1 day ago
The news could catapult us into Pennie’s, silver, quarters quickly here in my opinion. Low float and smart people are loading
👍️0
2times2
1 day ago
yes, NITE is just retail. GTSM is (as usual here) hiding the true ask...that is annoying.
👍️ 1
ace65
1 day ago
Yeah nice news now we just need GTSM to get off the ask with his 10k showing
👍️0
2times2
1 day ago
I am here (but silent) for months. Initially I bought 0003s. Sold higher. Yesterday bought a few M freebies back at 0004/3. Today bought an additional M at 0005 since it should climb upon todays update. For me until further notice its a flipping opportunity.
👍️0
delerious1
1 day ago
An FDA Committee Voted in Favor of Peptides—Despite the Agency's Opposition Alana Semuels
by
Alana Semuels
Senior Correspondent
Jul 23, 2026 4:19 PM ET
The U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland.Valerie Plesch/Bloomberg—Getty Images
In a highly unusual move, a U.S. Food and Drug Administration (FDA) committee voted against FDA staff’s own advice in a meeting on July 23, recommending that two peptides, called BP-157 and KPV, be added to a list that will allow certain specialty pharmacies to dispense them. Currently, those peptides—and the other five being considered—are in a legal gray area.
Here’s what to know.
What are peptides?
Peptides are short chains of amino acids, which are the building blocks of proteins. Peptide concoctions have grown in popularity over the past several years as injectable substances that proponents claim improve energy, sleep, sex drive, and more. U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has supported reclassifying peptides to improve people’s access to them. However, experts have expressed concern that there is little scientific evidence to support the peptides being considered.
Why is an FDA committee meeting about peptides?
The FDA convened the committee meeting on July 23 and 24 to debate whether to recommend that seven popular peptides be included on a list, called the 503A bulks list, that would allow compounding pharmacies to dispense them. Many of the voting members on the committee consult with or are employed by companies that could promote or dispense peptides. Usually, these FDA panels are composed of academics and researchers.
The committee’s recommendation is not a binding decision, and the addition of BP-157, KPV, and any other peptides to the list will still have to go through a lengthy public rulemaking process.
But it is unprecedented for a drug to be put on the pathway to widespread adoption in this manner instead of having to go through the more arduous and evidence-based FDA drug approval process, experts say. Most drugs are not dispensed through compounding pharmacies at all but are instead approved by the FDA and manufactured by drug companies under strict FDA supervision.
Why are these peptides being discussed?
In 2023, the seven peptides being discussed—BPC-157, KPV, TB-500, MOTS-C, Emideltide, Epitalon, and Semax—were among more than a dozen that the FDA essentially banned compounding pharmacies from dispensing, saying that they “may present significant safety risks.” Compounding pharmacies are specialty pharmacies that produce drugs with a doctor’s prescription; they are not subject to the type of FDA oversight that drug manufacturers are, but are instead largely overseen by state boards of pharmacy.
Since that 2023 ban, consumers have turned to alternative sources—including suppliers in China—which puts them in danger, advocates for peptides say. In testimony on July 23, Dr. Anant Vinjamoori, chief medical officer at the telehealth company Hims & Hers, said that a colleague had recently sent him a photo of a bodega in Queens selling peptides. “This is the real alternative to FDA's permission of legitimate pharmacies to compound peptides in controlled conditions,” he said. (Both Hims & Hers and Noom, a weight-management company, advocated before the vote for peptides to be allowed to be made at compounding pharmacies.)
What did the committee decide?
BP-157, a synthetic 15-amino acid peptide sometimes used to treat ulcerative colitis, and KPV, which is used for inflammatory conditions, were the first peptides considered on July 23 for addition to the 503A bulks list. Both were approved.
On BP-157, eight members of the committee voted yes, six voted no, and one abstained. The “yes” votes were largely from committee members who represent or advise telehealth companies, which broadly stand to benefit financially from the widespread adoption of peptides. Many of the people who voted “yes” said they wanted compounding pharmacies to dispense peptides because the alternative—patients getting the drug in the gray market—was worse.
“As a physician, I have to make sure that I'm keeping patients as safe as possible. That's my mandate, right? Do no harm,” said Dr. Haleem Mohammed, chief medical officer of Gameday Men’s Health, a telehealth firm, during the hearing. “So when I look at something like saying no to this and pushing it to the gray market, am I doing greater harm? And that's why I lose sleep at night.”
Mohammed went on to vote “yes,” recommending that BP-157 be placed on the 503A bulks list. (He also voted “yes” on KPV.) He later said that he voted “yes” in part for “medical freedom.” That term was echoed by the American Academy of Peptide Medicine, an industry group that has been lobbying for the inclusion of peptides on the list; its founder later said in a statement that the committee “voted to restore medical freedom and medical liberty for all of us.”
What did the opposition say?
People opposing these peptides’ inclusion on the list argued that little has changed since the FDA prohibited compounding pharmacies from dispensing these seven peptides in 2023.
In preparatory documents for the meeting, FDA staff said that it believed the evaluation criteria “weigh against” placing BPC-157 on the list because there was limited evidence about the peptide’s effectiveness and because there are other FDA-approved treatments for ulcerative colitis. The only trial FDA staff were able to find about the effectiveness of using BPC-157 to treat ulcerative colitis was a meeting abstract reporting on the results of a study using 46 people in which the peptide was given as an enema, not as an injection.
FDA staff also said that the evaluation criteria “weigh against” placing KPV on the list. None of the studies that staff found in its evaluation of the peptide were in humans.
“I'm concerned that we're responding to a market-induced demand rather than a decision based in solid science,” said committee member Dr. Elizabeth Rebello, executive director of anesthesiology, critical care, and pain medicine at the University of Texas MD Anderson Cancer Center.
The FDA usually relies on clinical trials when it is looking at adding a substance to the 503A bulks list, which determines what ingredients compounding pharmacies can use in mixing drugs. There are not yet significant clinical trials for these peptides, but some doctors, patients, wellness influencers, and Kennedy have voiced support for opening up the market for these drugs.
“The substance's supposed benefits are largely based on anecdotal evidence, and the interest in it appears to be driven by those who stand to benefit from increased demand,” said Nina Zeldes, a researcher at Public Citizen's Health Research Group, a nonprofit watchdog group, in testimony on the morning of July 23 opposing the inclusion of BP-157.
What might this mean for peptides in the U.S.?
An audible gasp rippled through the room after the tally of the votes was announced for BPC-157. Some committee members said that they worried about the implications of the FDA allowing itself to skip over clinical trials when permitting pharmacies to dispense medications.
“As a consumer representative, I worry what placing a bulk substance on the list conveys in terms of FDA approval,” said committee member Todd Durham, senior vice president of clinical outcomes and research at the Foundation Fighting Blindness, who voted “no” on adding these peptides to the list.
This vote could also create even more safety concerns by allowing consumers to buy non-FDA-approved medications from pharmacies that are not rigorously supervised by the FDA, says Shabbir Safdar, executive director of the Partnership for Safe Medicines, a public-health group that aims to protect consumers from counterfeit or unsafe medicines. He is concerned about the standards at 503A compounding pharmacies; one of the board members of the organizations, Dr. Kenneth McCall, published a paper in 2025 finding that compounded GLP-1s were linked to higher rates of adverse effects than non-compounded products between 2018 and 2024, including more abdominal pain, diarrhea, and nausea. Reporting of prescribing and preparation errors were also higher for compounded medications, the paper found.
Safdar says he knows of several instances when people had serious health problems after taking compounded medications. He worries that people will think that these peptides have robust clinical evidence behind them as a result of being added to the list.
“Allowing peptides to be compounded removes incentives to go through FDA's rigorous drug approval process,” said Dr. Peter Lurie, a former FDA associate commissioner and the president of the Center for Science in the Public Interest, during his testimony at the meeting. “Any company that aspires to prove the safety and effectiveness of a peptide will turn away from them, knowing that compounders will simply be able to sell them without ever needing to generate safety and effectiveness evidence.”
Indeed, Lurie continued, financial analysts are predicting a $2.2 billion telehealth marketing opportunity if these seven peptides are approved for compounding. Him & Hers stock rose more than 10% after the BPC-157 vote. 👍️ 1
Chartmaster
1 day ago
Fifty 1 Labs Outlines Planned U.S. Telehealth Peptide Services Platform Model expected to include digital intake, clinician evaluation, prescription routing, monitoring coordination, and subscription-based patient support
VANCOUVER, BC / ACCESS Newswire / August 7, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY) today provided an overview of its planned U.S. - focused telehealth peptide services platform. The Company intends to develop a patient-facing service model that complements its peptide science and commercialization strategy while remaining separate from investigational clinical-development programs.
The planned platform is expected to allow patients to complete digital intake, schedule virtual or in-person consultations, and receive evaluation by appropriately licensed healthcare professionals. Where a clinician determines that a peptide therapy is medically appropriate and legally available, prescriptions may be transmitted to qualified compounding pharmacies for dispensing. The Company expects that clinical services may be supported by licensed physicians, nurse practitioners, naturopathic doctors where authorized by state law, and other qualified clinicians acting within the scope of their licensure.
Fifty 1 Labs anticipates that the telehealth service line may generate revenue through monthly membership fees, virtual visit fees, care-management services, laboratory and monitoring coordination, patient-support services, and pharmacy-related service arrangements where legally permissible. The Company intends to structure such arrangements in compliance with federal and state healthcare laws, telemedicine rules, pharmacy and compounding requirements, fee-splitting limitations, referral rules, advertising restrictions, privacy laws, and professional-practice requirements.
"Telehealth can improve access, but it must be built with the right guardrails," said Joel J. Gagnier, Ph.D., MSc, N.D., Chief Executive Officer of Fifty 1 Labs. "Our priority is to create a clinically responsible model with appropriate intake, documentation, medical oversight, monitoring, patient education, adverse-event processes, and compliance review."
The Company does not intend to represent that any peptide is approved for a use for which it is not approved. The timing and launch of the telehealth service line remain subject to regulatory review, clinician contracting, pharmacy integration, technology development, insurance, state-by-state legal analysis, and financing.
About Fifty 1 Labs, Inc.
Fifty 1 Labs, Inc. is a biotechnology and health-sciences company focused on peptide products, peptide sciences, AI-enabled discovery, musculoskeletal health, sports recovery, and planned U.S. telehealth peptide services. The Company's strategy includes R&D, partnerships, potential acquisitions, clinical-development planning, and commercialization pathways where legally permissible.
Contact:
Investor Relations
Fifty1 Labs, Inc.
ir @Ocean789
www.fifty1labs.com
Forward-Looking Statements
Safe Harbor Statement:
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, identified by words such as "may," "will," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, involve risks and uncertainties that could cause actual results to differ materially from those projected. Such risks include, but are not limited to, general economic conditions, competition, technological changes, and other factors detailed in the company's Disclosure Statements. The company undertakes no obligation to update these statements.
SOURCE: Fifty 1 Labs, Inc.
View the original press release on ACCESS Newswire
© Copyright 2026 ACCESS Newswire. All Rights Reserved. 👍️ 1
NebraskaOTC
2 days ago
Yep... good ol' Gollum got ya again! $FITY is.... always has been.... always will be.... a front loaded SCAM.
But... but...."I'm a medical EXPERT!!!!"
Track record speaks for itself, Eh FAM???
But... but.... $FITY has cool AI posters! LMAO!!!!!
$FITY is a SCAM. PERIOD.
Right FAM??? 👍️0
Crazyjb
2 days ago
Yea back up !°p
👍️ 1
🔥 1
😎 1
🚀 1
thesmallguy
2 days ago
Well I guess we know where it's headed.
👍️0
Crazyjb
2 days ago
Most likely we'll we shall rise again imo
👍️0
trender18
2 days ago
Maybe some traders got tired of wating for the stock to move, and decided to take a loss and move on.
👍️0
Crazyjb
2 days ago
Looks like sell still go n on
👍️ 1
Crazyjb
4 days ago
Looks like everyone leaving but me lol
👍️ 1
😎 1
Crazyjb
5 days ago
Who knows lol
👍️0
thesmallguy
5 days ago
Loading Zone maybe?
👍️0
train21
6 days ago
$FITY ................going the wrong way are they dumping shares
because nobody selling at a loss ? 👍️0
train21
6 days ago
$FITY ................going the wrong way are they dumping shares
because nobody selling at a loss ? 👍️0
Crazyjb
7 days ago
Let's go got my right alias
👍 2
😎 1
Crazyjb
1 week ago
Musta gt few 4s today huh
👍️0
train21
1 week ago
$FITY LETS GO HERE GET THIS STOCK MOVING ALREADY 👍️0
train21
1 week ago
$FITY LETS GO HERE GET THIS STOCK MOVING ALREADY 👍️0
Crazyjb
1 week ago
Or they will just b handed shares 🤔
👍️0
Crazyjb
1 week ago
Soon bid sitters will have to chase imo
🔥 1
Kjv
1 week ago
They have been updating that daily. Yes. No direct dilution has happened here in a longtime except for preferred share conversions 👍️0
Crazyjb
1 week ago
Maybe give us a little boost
👍️0
ace65
1 week ago
Unchanged SS updated today ,last three months no change.
👍️0
WillForeall
1 week ago
Too damn funny the lengths folks will go to deceive others. Data from 2011 and just last year this company changed its name and ticker symbol if I do believe so…
👍️0
Aquahoya
1 week ago
Thus, perhaps thus the nets out at .0004.
👍️0
trender18
1 week ago
https://stockanalysis.com/quote/otc/FITY/statistics/
👍️0
Aquahoya
1 week ago
Are you sure you are on the right company?
👍️0
trender18
1 week ago
Balance Sheet The company has 30,493 in cash and 14.40 million in debt, with a net cash position of -14.37 million or -0.01 per share.
Cash & Cash Equivalents 30,493
Total Debt 14.40M
Net Cash -14.37M
Net Cash Per Share -0.01
Equity (Book Value) -9.98M
Book Value Per Share -1.06
Working Capital -10.01M 👍️0
Crazyjb
1 week ago
Oh no double digits red lol
👍️0
Crazyjb
1 week ago
Damn it it was supposed to change
👍️0
Crazyjb
1 week ago
Not the oracle witch no more!!!
👍️0
Kjv
1 week ago
Fact.2 of those notes were due in the past and there wasn’t even a problem! Yes! Your numbers are right on liabilities.
I will like him to show us where he saw millions. 👍️0
Aquahoya
1 week ago
The balance sheet as of last quarter shows a total liabilities of $191,676. Not sure what you are talking about. If you look at all the debt, it comes to $246,000 roughly. Most like the note will be renegotiated.
💯 1
